Evidence map›Paper›PMID 41733621›Full record

ReviewHerz2026

M-TEER-interventional repair of mitral valve regurgitation.

Christos Iliadis, Stephan Baldus

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christos IliadisFaculty of Medicine and University Hospital Cologne, Department III for Internal Medicine, University of Cologne, Cologne, Germany. christos.iliadis@uk-koeln.de.
Stephan BaldusFaculty of Medicine and University Hospital Cologne, Department III for Internal Medicine, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as an alternative therapy for mitral regurgitation (MR), addressing the unmet clinical need for patients with high surgical risk. Previous large randomized controlled trials (RCTs), including EVEREST II, COAPT, and MITRA-FR, have established the safety and efficacy of M‑TEER for both etiologies of MR: primary (PMR) and secondary MR (SMR). The field of SMR treatment has been updated by the recent RCTs RESHAPE-HF2 and MATTERHORN, which have expanded the recommendations of M‑TEER in the current European guidelines. This article summarizes key evidence from pivotal trials, discusses patient selection, and presents ongoing studies in the field of M‑TEER.

Indexed as

Mitral Valve AnnuloplastyMitral Valve InsufficiencyTranscatheter Mitral Valve ReplacementEvidence-Based MedicineHumansPatient SelectionTreatment OutcomeGuidelinesMitral valve regurgitationPatient selectionTranscatheter edge-to-edge repairTreatment

Identifiers

PMID41733621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.